According to a recent market study published by Growth Market Reports, titled, “Monoclonal Antibodies Market by Type, by Application, by End-use, and by Region: Size, Share, Trends and Opportunity Analysis, 2015-2030”, the market was valued at US$ 1,49,684.6 Million in 2021 and is expected to expand at a growth rate of 12.7 % by 2030.

Request a free sample copy @ https://growthmarketreports.com/request-sample/4881

Monoclonal antibodies are molecules manufactured or synthesized in the laboratory to serve as soldiers for the body. These antibodies enhance, restore, mimic or modify the immune system's attack on cells that aren't required or foreign to the body, such as cancer cells.

Monoclonal antibodies act in different modes that include: Flagging cancer cells, Triggering cell-membrane destruction, Blocking cell growth by inhibiting the proteins, Preventing blood vessel growth required for the growth of cancerous cells, Blocking immune system inhibitors for the immune system cells to work against cancer cells, Directly attacking cancer cells, Delivering radiation treatment, Delivering chemotherapy, and Binding cancer and immune cells (Some drugs combine two monoclonal antibodies, one that attaches to a cancer cell and one that attaches to a specific immune system cell to enhance the immune system attack for cancer cells).

The monoclonal antibodies market has been fragmented based on type, application, and end-use. By type, the global monoclonal antibodies market is categorized as murine, chimeric, humanized, and human. In terms of application, the market is categorized as cancer, autoimmune diseases, neurological diseases, infectious diseases, and others. By end-use, the market is segmented into hospitals, specialty centers, and others. Considering regions, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

The Coronavirus disease 2019 (COVID-19) pandemic highlighted economic disparities, global interdependence, and governance challenges. However, the COVID-19 outbreak boosted the production and consumption rate of monoclonal antibodies, due to the lack of a defined line of treatment during the pandemic. The pandemic disrupted various businesses and supply chains.

The production chain for these therapeutic agents was retained and doubled. Monoclonal antibodies proved to be effective for those patients who were immune-compromised and had been suffering from chronic ailments. During the pandemic, many antibodies in clinical trials were used to treat severe medical conditions in patients.

As per growth market reports industry analyst, Ruchika Sharma, “The expanding healthcare and R&D activities are expected to contribute to the growth of the global monoclonal antibodies market. Advances in research and development, treatment for autoimmune diseases, and the rising prevalence of diseases are contributing to the expansion of the monoclonal antibodies market. The shelf life of mAbs is less, hence the production and consumption of mAbs go hand in hand. Usually, companies do not keep heavy inventories, and the maintenance of storage conditions is costly. In the coming years, the demand for monoclonal antibodies is projected to grow.

A supply chain is a network between manufacturers and suppliers to produce and distribute a specific product to the final buyers. This network includes different people, regulatory bodies, entities, information, and resources. Entities in the supply chain include raw material suppliers, manufacturers, logistics, warehouses, pharmacies, finance, distributors, and customers. Supply chain management is an essential part of any business. If the supply chain of monoclonal antibodies is hampered, the patients suffering from chronic ailments are not treated on time, resulting in the death of patients.

Key Takeaways from the Study

  • Players in the global monoclonal antibodies market include AbbVie Inc., Janssen Biotech, Inc., Amgen Inc., AstraZeneca, Lilly, Merck & Co., Inc., Abbott, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited held a major market share of the monoclonal antibodies market in 2021.
  • Employment of advanced genetic engineering technology and the increasing prevalence of chronic diseases such as cancer and autoimmune diseases are contributing to the growth of the global monoclonal antibodies market.
  • In terms of type, the global monoclonal antibodies market is categorized as murine, chimeric, humanized, and human. The human segment is projected to account for a substantial share of the monoclonal antibodies market during the forecast period. Human-type monoclonal antibodies are made of human proteins and do not induce a vigorous immune reaction in the body when given to the patients intravenously. Fully human mAbs are produced in transgenic mice that have been genetically engineered with the human immunoglobulin locus
  • Based on applications, the global monoclonal antibodies market is categorized as cancer, autoimmune diseases, neurological diseases, infectious diseases, and others. The cancer segment is projected to hold a significant share of the market during the forecast period, as the prevalence of cancer is high and the utilization of monoclonal antibodies for cancer treatment is at its peak. For example, trastuzumab (Herceptin) is highly used to treat HER2-positive breast cancer and stomach cancer.
  • In terms of regions, the global monoclonal antibodies market is divided into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to account for a significant share of the monoclonal antibodies market during the forecast period, owing to the increasing facilities for treatment and well-established healthcare system in the region. Europe holds a large share of the market, due to rising R&D activities in the region.

Report Scope

Report Metric

Details

Market Value in 2021

US$ 1,49,684.6 Million

Market Growth Rate (from 2020 to 2028)

12.7 %

Historical Data

2015 & 2020

Base Year

2021

Forecast Period

2022 – 2030

Units Considered

Value (US$ Million)

Market Segments

By type, By Application, By End-use, and By Region

Key Companies Profiled

AbbVie Inc., Janssen Biotech, Inc., Amgen Inc., AstraZeneca, Lilly, Merck & Co., Inc., Abbott, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Manufacturers and distributors.
  • Demand Side: Healthcare industry - Pharmaceutical industry.
  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.
  • Associations and Industry Bodies: Food and Drug Administration (FDA), World Health Organization (WHO), Center for Biologics Evaluation and Research (CBER), among others.